Abstract

Global Market Access for Companion Diagnostics

Kristin Ciriello Pothier, Partner & Managing Director/Life Sciences Leader, Ernst and Young LLP

The companion diagnostics space is evolving rapidly: across therapeutic areas, our understanding of disease biology is becoming ever more targeted and profound, enabling physicians to match a treatment to an illness more precisely than ever before. To deliver fully on the promise of personalized medicine, however, diagnostics providers will need to new marketing strategies while pharmaceutical companies will need to proactively develop partnerships – and re-consider what a partnership can be. Come discuss the future of personalized medicine with the EY Precision Medicine team, discussing a macro view of the PM space and an understanding of clinically relevant challenges and opportunities facing the industry. This conversation will give the audience a thorough understanding of the current CDx market from a clinical and commercial perspective, with emphasis on trends in innovation and marketing in companion diagnostics. Ultimately, the team will share a perspective on how the industry is poised to move forward.